Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases-Reference-Cited by-同舟云学术

Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases

Published:2009-06 Issue:6 Volume:15 Page:539-550
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Liu Shuying,Umezu-Goto Makiko,Murph Mandi,Lu Yiling,Liu Wenbin,Zhang Fan,Yu Shuangxing,Stephens L. Clifton,Cui Xiaojiang,Murrow George,Coombes Kevin,Muller William,Hung Mien-Chie,Perou Charles M.,Lee Adrian V.,Fang Xianjun,Mills Gordon B.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference65 articles.

1. Living with p53, dying of p53;Aylon;Cell,2007

2. Carba analogs of cyclin phophatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis;Baker;J. Biol. Chem.,2006

3. Smoldering and polarized inflammation in the initiation and promotion of malignant disease;Balkwill;Cancer Cell,2005

4. Adjustment of systematic microarray data biases;Benito;Bioinformatics,2004

5. Controlling the false discovery rate: a practical and powerful approach to multiple testing;Benjamini;J. R. Statist. Soc. B,1995

Cited by 335 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel—An In Silico and In Vitro Study;Molecules;2024-09-10

2. Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications;International Journal of Molecular Sciences;2024-07-15

3. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer;Cell Death Discovery;2024-03-15

4. Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells;BMC Medicine;2024-03-14

5. High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma;Hepatology Research;2024-03-02